Lord, Christopher J <br/><br/>
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.  [electronic resource] 

 -  Annual review of medicine  2015 
 - 455-70 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1545-326X 
<br/><br/><label>Standard No.: </label>10.1146/annurev-med-050913-022545  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Benzamides--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Drug Resistance, Neoplasm<br/>Enzyme Inhibitors--therapeutic use<br/>Female<br/>Genes, BRCA1<br/>Genes, BRCA2<br/>Humans<br/>Mutation<br/>Neoplasms--drug therapy<br/>Neoplasms, Cystic, Mucinous, and Serous--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Phthalazines--therapeutic use<br/>Piperazines--therapeutic use<br/>Poly (ADP-Ribose) Polymerase-1<br/>Poly(ADP-ribose) Polymerase Inhibitors